Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 CAR-T for R/R CD7+ Peripheral T-Cell Lymphoma
NCT05979792Phase 1Not yet recruiting
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of RD13-02 in peripheral T-cell lymphoma (PTCL). Primary endpoint: Dose-limiting toxicity at 2 years. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
RD13-02
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05979792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979792.